Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [31] Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review
    Beal, Eliza W.
    Suarez-Kelly, Lorena P.
    Kimbrough, Charles W.
    Johnston, Fabian M.
    Greer, Jonathan
    Abbott, Daniel E.
    Pokrzywa, Courtney
    Raoof, Mustafa
    Lee, Byrne
    Grotz, Travis E.
    Leiting, Jennifer L.
    Fournier, Keith
    Lee, Andrew J.
    Dineen, Sean P.
    Powers, Benjamin
    Veerapong, Jula
    Baumgartner, Joel M.
    Clarke, Callisia
    Mogal, Harveshp
    Russell, Marti C.
    Zaidi, Mohammed Y.
    Patel, Sameer H.
    Dhar, Vikrom
    Lambert, Laura
    Hendrix, Ryan J.
    Hays, John
    Abdel-Misih, Sherif
    Cloyd, Jordan M.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [32] The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases
    van der Werf, L. R.
    Wassenaar, E.
    de Niet, A.
    Lalezari, F.
    Braam, H. J.
    van Ramshorst, B.
    Nederend, J.
    de Hingh, I. H. J. T.
    Kok, N. F. M.
    Aalbers, A. G. J.
    EJSO, 2019, 45 (03): : 376 - 382
  • [33] Peritoneal metastatic colorectal Cancer: cytoreductive Surgery and hyperthermic intraperitoneal Chemotherapy
    Koenigsrainer, I.
    Beckert, S.
    Bruecher, B.
    Zieker, D.
    Koenigsrainer, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (36) : 1811 - 1814
  • [34] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review
    Parikh, Manasi S.
    Johnson, Paul
    Romanes, Jonathan Paul
    Freitag, Harvey E.
    Spring, Mary E.
    Garcia-Henriquez, Norbert
    Monson, John R. T.
    DISEASES OF THE COLON & RECTUM, 2022, 65 (01) : 16 - 26
  • [35] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era
    Michael Eamon Kelly
    Edward Murphy
    Alan Martin Keyes
    Mohammad Faraz Khan
    Jarlath C. Bolger
    Josh Grundy
    John Conneely
    John MacHale
    John McCaffrey
    Ronan Cahill
    Brendan Moran
    Conor Shields
    Jürgen Mulsow
    Irish Journal of Medical Science (1971 -), 2021, 190 : 1373 - 1377
  • [36] Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer
    Pompiliu Piso
    Kathrin Stierstorfer
    Michael Gerken
    Monika Klinkhammer-Schalke
    International Journal of Colorectal Disease, 2018, 33 : 1559 - 1567
  • [37] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes
    Rosa, Fausto
    Galiandro, Federica
    Ricci, Riccardo
    Di Miceli, Dario
    Quero, Giuseppe
    Fiorillo, Claudio
    Cina, Caterina
    Alfieri, Sergio
    LANGENBECKS ARCHIVES OF SURGERY, 2021, 406 (08) : 2797 - 2805
  • [38] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A pragmatic comparison of oncological outcomes in synchronous versus metachronous disease
    Aguirre-Allende, Ignacio
    Pereira-Perez, Fernando
    Manzanedo-Romero, Israel
    Fernandez-Briones, Paula
    Munoz-Martin, Maria
    Serrano-Moral, Angel
    Perez-Viejo, Estibalitz
    SURGICAL ONCOLOGY-OXFORD, 2025, 58
  • [39] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal Cancer-An Overview of Current Status and Future Perspectives
    Graf, Wilhelm
    Ghanipour, Lana
    Birgisson, Helgi
    Cashin, Peter H.
    CANCERS, 2024, 16 (02)
  • [40] Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Devilee, R. A.
    Simkens, G. A.
    van Oudheusden, T. R.
    Rutten, H. J.
    Creemers, G. J.
    ten Tije, A. J.
    de Hingh, I. H.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (09) : 2841 - 2848